Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Raises $27.1M in Share Placement

NEW YORK (GenomeWeb News) – Galapagos, the Belgian drug development and drug screening services firm, has raised €18.2 million ($27.1 million) through the placement of 2,125,925 new ordinary shares at a price of €8.55 per share.

The shares are being placed with unnamed international institutional investors. Delivery of the shares is expected to take place on Oct. 21.

Galapagos plans to use the funds to support clinical development of drug candidates, including a phase II study of a rheumatoid arthritis drug.

The firm did not say whether any of the proceeds will be used by its BioFocus DPI division, which conducts drug validation and screening services.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more